Comparative pharmacokinetics of verapamil and norverapamil in normal and ulcerative colitis rats after oral administration of low and high dose verapamil by UPLC-MS/MS

Xenobiotica ◽  
2019 ◽  
Vol 50 (6) ◽  
pp. 713-721
Author(s):  
Hongping Yao ◽  
Changhe Wang ◽  
Wen Lu ◽  
Wen Li ◽  
Wanghui Jing ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Oral Administration ◽  
High Dose

Oat β-glucan ameliorates dextran sulfate sodium (DSS)-induced ulcerative colitis in mice

2015 ◽  
Vol 6 (11) ◽  
pp. 3454-3463 ◽  
Author(s):  
Bo Liu ◽  
Qinlu Lin ◽  
Tao Yang ◽  
Linna Zeng ◽  
Limin Shi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Oral Administration ◽  
Inflammatory Cytokines ◽  
Dextran Sulfate ◽  
Dextran Sulfate Sodium ◽  
Tnf Α

Oral administration of oat β-glucan ameliorates DSS induced colitis in mice by decreasing the expression of inflammatory cytokines TNF-α, IL-1β, IL-6 and iNOS.

A RARE ASSOCIATION OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY WITH ULCERATIVE COLITIS

2021 ◽  
pp. 18-19
Author(s):  
Nilima K. Shah ◽  
Ankita Patel ◽  
Umeshkumar Nakum ◽  
Ravindra Patel
Keyword(s):  
Ulcerative Colitis ◽  
Ulcerative Colitis Patient ◽  
Chronic Inflammatory Demyelinating Polyneuropathy ◽  
Rare Complication ◽  
Gastrointestinal Symptoms ◽  
Demyelinating Polyneuropathy ◽  
High Dose ◽  
Initial Symptom ◽  
Colitis Patient ◽  
Rare Association

Chronic inammatory demyelinating polyneuropathy (CIDP) is a rare complication of Ulcerative colitis and it is uncertain whether it is associated with Ulcerative colitis itself or with its treatment. We describe a case of CIDP-like neuropathy as an initial symptom of Ulcerative colitis. A 17 years old male patient presented with symmetrical weakness of both lower extremities with paresthesia of both hand and feet. With impression of AIDP patient was treated with plasmapheresis and discharged on tapering steroid therapy. After 3 months again presented with bilateral weakness of all four limbs associated with diarrhea and fever. Patient was diagnosed with Ulcerative colitis ,so considering previous episode as 1st episode of CIDP and with rare association with Ulcerative colitis . Patient was treated with high dose of steroids and immunosuppressive therapy. Neurological and gastrointestinal symptoms remarkably improved after treatment.

Mechanism of Traditional Medicine Tongfeng Li’an Granules on Hyperuricemic Rats Based on Regulating Uric Acid Transporter

2021 ◽  
Vol 15 (4) ◽  
pp. 536-541
Author(s):  
Xiangpei Zhao ◽  
Li Li ◽  
Chuanmei Zhong ◽  
Hongli Teng ◽  
Guodong Huang
Keyword(s):  
Uric Acid ◽  
Oral Administration ◽  
Natural Product ◽  
Serum Uric Acid ◽  
Rat Model ◽  
Regulatory Mechanism ◽  
High Dose ◽  
Model Group ◽  
Serum Biochemical ◽  
Acid Transporter

Hyperuricemia (HUA) is a metabolic disorder of purine metabolism which leads to the increase of serum uric acid. Tongfeng Lian granule (TFLA) is a clinical empirical traditional herb prescription in China, is biobased natural product material. To study its regulatory mechanism on uric acid transporter in rats with HUA, the rat model of hyperuricemic was established by oral administration of potassium oxazinate (1.5 g/kg) and adenine (0.05 g/kg). The related indexes were detected to evaluate the uric Acid Transporter after treat with TFLA. In the results, compared with model group, the high dose TFLA can reduce the levels of Related serum biochemical indexes (*P < 0.05, **P < 0.01). TFLA could reduce the levels of URAT1, GLUT9 and increase the expression of OAT3 in kidney. In conclusion, TFLA can effectively inhibit the level of serum uric acid with hyperuricemia rats, and the possible mechanism related to TFLA inhibiting the reabsorption of uric acid by URAT1 and GLUT9, promoting the secretion of OAT3 and uric acid into urine.

scholarly journals Efficacy of 5-Aminosalicylic Acid Enemas in the Treatment of Distal Ulcerative Colitis

1990 ◽  
Vol 4 (7) ◽  
pp. 468-471 ◽  
Author(s):  
MG Robinson ◽  
DL Decktor
Keyword(s):  
Ulcerative Colitis ◽  
Disease Activity ◽  
Activity Index ◽  
Disease Activity Index ◽  
First Episode ◽  
High Dose ◽  
Aminosalicylic Acid ◽  
Open Label ◽  
Distal Ulcerative Colitis ◽  
The Mean

The efficacy of 4 g 5-aminosalicylic acid (5-ASA, mesalamine) enemas was assessed in 666 patients with distal ulcerative colitis. Patients were enrolled in an open-label compassionate use program. One 4 g 5-ASA enema was administered each night for a period of four weeks and the disease activity index was assessed at baseline and on days 14 and 28. On days 14 and 28, 78.0% and 88.1% of patients, respectively, demonstrated an improvement in disease activity index. The mean decline in disease activity index on day 14 was 40.7% (P=0.0001) and on day 28 it was 55.4% (P=0.0001). Efficacy was similar whether the disease was confined to or extended beyond 30 cm from the anus. There was no difference in efficacy in patients suffering their first episode of disease compared to patients suffering subsequent attacks. In conclusion, high dose 5-ASA enemas are a highly effective treatment for distal ulcerative colitis.

Oral administration of colitis tissue-accumulating porous nanoparticles for ulcerative colitis therapy

2019 ◽  
Vol 557 ◽  
pp. 135-144 ◽  
Author(s):  
Qiubing Chen ◽  
Shuangquan Gou ◽  
Panpan Ma ◽  
Heliang Song ◽  
Xin Zhou ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Oral Administration ◽  
Porous Nanoparticles

Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients

Pharmacology ◽  
2019 ◽  
Vol 104 (1-2) ◽  
pp. 51-56 ◽  
Author(s):  
Hideki Ishikawa ◽  
Michihiro Mutoh ◽  
Takashi Abe ◽  
Takeshi Nakajima ◽  
Yoji Takeuchi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Familial Adenomatous Polyposis ◽  
High Dose ◽  
Clinical Report ◽  
Colon Polyps ◽  
Adenomatous Polyposis ◽  
Polyp Size ◽  
Double Blind ◽  
Standard Drug ◽  
Intestinal Polyp

Mesalazine is the gold standard drug for treatment of ulcerative colitis (UC). Here, we describe 4 cases of familial adenomatous polyposis (FAP) patients with UC that showed reduction of intestinal polyp diameter by mesalazine treatment. Of note, the effects of mesalazine on the development of intestinal polyps in FAP patients have not been reported, and we further investigated whether the short-term use of high-dose mesalazine (4 g/day) has harmful effects on FAP patients or not. The authors found that the treatment showed slightly adverse events in FAP patients. However, mesalazine tended to reduce the number of colon polyps in male subjects with FAP. This report provides basic information for planning a double-blind, randomized, clinical trial that aims to show mesalazine’s potential to suppress intestinal polyp development in FAP.

Sign in / Sign up

Export Citation Format

Share Document